1. [Is monotherapy with β-lactam antibiotics still up to date? New aspects for treatment of severe infections].
- Author
-
Heizmann P, Lode H, and Heizmann WR
- Subjects
- Animals, Anti-Bacterial Agents adverse effects, Bacteria drug effects, Bacteria immunology, Bacterial Infections immunology, Cell Wall drug effects, Cell Wall immunology, Drug Therapy, Combination, Exotoxins blood, Guideline Adherence, Humans, Immunization, Interleukin-8 blood, Sepsis immunology, Staphylococcal Infections drug therapy, Staphylococcal Infections immunology, Staphylococcus aureus drug effects, Staphylococcus aureus immunology, Virulence Factors antagonists & inhibitors, beta-Lactams adverse effects, Anti-Bacterial Agents therapeutic use, Bacterial Infections drug therapy, Critical Care, Cross Infection drug therapy, Sepsis drug therapy, beta-Lactams therapeutic use
- Abstract
Mortality of sepsis is still high. Crucial for therapeutic response are the early start of treatment as well as the choice of antibiotics or antibiotic combinations. β-lactam antibiotics with bactericidal mode of action are often recommended in guidelines. But this antibiotic class can trigger the immune system to a maximum by releasing cell wall components or exotoxins. This may lead to a worsening of the patient's clinical situation. In contrast, antibiotics with bacteriostatic action often inhibit bacterial protein synthesis with decrease of production of virulence factors and minimize release of cell wall components. The purpose of this review is to summarise the significance of some bacteriostatic antibiotics and to discuss whether a combination of bactericidal and bacteriostatic agents may improve the course of the illness.
- Published
- 2012
- Full Text
- View/download PDF